In The Global Politics of Pharmaceutical Monopoly Power,Ellen ’t Hoen explains how the new global rules for pharmaceutical patenting are affecting access to medicines in the developing world. The book gives an account of the current debates on intellectual property, access to medicines and medical innovation, and provides historical context that explains how the current system emerged.
’t Hoen assesses the sometimes courageous, sometimes inexcusable measures the international community and governments have taken in response to the high prices of medicines. She explains not only the events that led to dramatically improved access to AIDS treatment in developing countries, an issue that has long been in the media spotlight, but also considers how the system affects access to all new medicines. Her book supports major policy changes in the management of pharmaceutical patents and the way medical innovation is financed in order to protect public health and, in particular, promote access to essential medicines for all.
Table of Contents
List of abbreviations and acronyms
Timeline of events
Acknowledgements
Executive Summary
1. Introduction
2. Key IP-related issues in access to new essential medicines
3. History of the debate on intellectual property protection and pharmaceuticals
4. The Doha Declaration on TRIPS and Public Health
5. Practical implementation of the Doha Declaration on TRIPS and Public Health
6. Attempts to limit the scope and use of the Doha Declaration
7. Rationale for the pharmaceutical patent system
8. Conclusions and recommendations
References
Annex
- Annex 1: Declaration on the TRIPS Agreement and Public Health
- Annex 2: Selected Articles from TRIPS
- Annex 3: 2005 Indian Patents (Amendment) Act, Section 3(d)
- Annex 4: 2003 WTO ‘August 30th’ Decision
- Annex 5: Negotiating history of the ‘August 30th Decision’